Actively Recruiting
Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer
Led by Haukeland University Hospital · Updated on 2024-03-19
61
Participants Needed
1
Research Sites
444 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Diarrhea was the most frequently reported severe adverse event in the treatment regime of pre-operative sequential short-course radiotherapy followed by chemotherapy (so called total neo-adjuvant treatment). This study therefore investigates the benefit of on-couch adaptation for locally advanced rectal cancer patients undergoing this treatment regime.
CONDITIONS
Official Title
Total Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with locally advanced rectal adenocarcinoma having at least one of: T4a, CRM+ (≤1 mm), N1c, N2, or extramural vascular invasion (EMVI+)
- Patients with pelvic sidewall lymph node involvement may also be considered
- ECOG performance status of 0 or 1
- Willing and able to provide full written consent for participation
You will not qualify if you...
- Previous treatment for rectal cancer
- Previous radiation to the treatment area, such as for prostate cancer
- Presence of hip prosthesis
- Contraindications to MRI
- Pregnancy
- Abnormal DPYD genotype
- Known contraindications to 5-FU, Capecitabine, or Oxaliplatin as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Haukeland University Hospital
Bergen, Norway, 5021
Actively Recruiting
Research Team
S
Sara Pilskog, PhD
CONTACT
U
Unn Hege Lilleøren, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here